We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Kininogen-1 Protein Linked to Early Cognitive Impairment in Parkinson’s

By LabMedica International staff writers
Posted on 03 Dec 2020
Cognitive impairment is a common feature in Parkinson's disease (PD), associated with increased morbidity and mortality. More...
An ongoing area of PD studies is the search for biomarkers that can provide prognostic information about cognitive impairment and other symptoms.

Cognitive impairment is a common non-motor symptom of Parkinson’s disease. Two distinct subtypes of cognitive dysfunction have been suggested in PD, including frontal executive dysfunction associated with dopaminergic loss, and the posterior/temporal subtype that affects visuospatial and semantic fluency function and correlates with cholinergic loss.

Clinical Neuroscientists at the Karolinska Institutet (Stockholm, Sweden) and their colleagues recruited 405 persons in the PD cohort of the AETIONOMY project in six university hospitals in France, Germany, and Sweden, between September 2015 and December 2017, including 251 patients with idiopathic PD, 25 with familial PD, 39 persons at risk for PD, and 90 healthy controls. Seventy-four Idiopathic PD patients with available cerebrospinal fluid (CSF) were included in the analyses.

A suspension bead array procedure was performed, utilizing polyclonal rabbit antibodies generated within the Human Protein Atlas project targeting 216 proteins. Proteins were selected either based on potential association to PD according to literature or by the teams’s previous neuroproteomic efforts. As a validation procedure, levels of kininogen in CSF were measured using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (Abcam, Cambridge, UK). Dilution ratio was 1:100 and absorbance was measured by a Tecan Spark 10‐M plate reader (Tecan Group Ltd., Männedorf, Switzerland).

The team reported that in initial statistical analyses, they identified three proteins that were present at significantly higher levels in the CSF of those with low scores: kininogen-1 (KNG1), a disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), and kallikrein‐6 (KLK6). In subsequent analyses, which made statistical adjustments for possible confounding factors, KNG1 was significantly predictive of the Repeatable Battery for the Assessment of the Neuropsychological Status (RBANS score); that is, individuals with high KNG1 levels in their CSF were statistically more likely to have low RBANS scores. The other two proteins were not significantly associated with the RBANS score in these models.

The authors concluded that the results of a high‐throughput antibody‐based proteomic approach for the analysis of CSF markers related to early signs of cognitive impairment in PD and found that KNG1 levels in CSF were altered in PD patients with RBANS total score of low average level or less. The study was published in the November, 2020 issue of the journal Movement Disorders.

Related Links:
Karolinska Institutet
Abcam
Tecan Group Ltd



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.